Abstract |
To evaluate the long-term impact of the reduction of Philadelphia chromosome (Ph)-positive metaphases by treatment of chronic myelogenous leukaemia (CML) with interferon (IFN) alpha, we examined the outcome of 62 patients who had been enrolled between 1984 and 1990 into 2 IFN trials at our institution. As best cytogenetic response, 9 patients had achieved a complete remission and an additional 9 patients a partial remission. The remaining 44 patients had obtained either a minimal (n=29) or no cytogenetic response (n=15). Of the total of 62 patients, 9 were still on schedule and responsive to IFN in January 1995, including 7 patients in ongoing complete cytogenetic remission. The overall 5-year survival rate after a median follow-up from diagnosis of 51 months (range 3-102 months) was 62% and the median survival was reached at month 87. The effect of cytogenetic remission on survival was examined by "landmark" studies showing a significant survival advantage for patients with karyotype responses. In conclusion, in the patients studied, cytogenetic improvement was found to translate into improved survival expectancy. Long-term control by IFN alpha of CML, however, was restricted to a small minority of patients, predominantly to those attaining a complete suppression of the leukaemic cell clone as judged by cytogenetic criteria.
|
Authors | O Kloke, N Niederle, B Opalka, I Hawig, S Seeber, R Becher |
Journal | European journal of haematology
(Eur J Haematol)
1996 Jan-Feb
Vol. 56
Issue 1-2
Pg. 78-81
ISSN: 0902-4441 [Print] England |
PMID | 8599999
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
|
Topics |
- Actuarial Analysis
- Adolescent
- Adult
- Aged
- Female
- Follow-Up Studies
- Genetic Techniques
- Humans
- Interferon alpha-2
- Interferon-alpha
(therapeutic use)
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(genetics, mortality, pathology, therapy)
- Male
- Metaphase
- Middle Aged
- Philadelphia Chromosome
- Predictive Value of Tests
- Prognosis
- Recombinant Proteins
- Remission Induction
- Survival Rate
- Time Factors
|